DORTMUND, Germany, October 8, 2018 /PRNewswire/ --
Taros Chemicals GmbH & Co. KG announced the appointment of Dr Torsten Hoffmann as Senior Vice President Drug Discovery. In his role, Torsten will further strengthen and accelerate Taros' continued growth of its drug discovery business.
(Logo: https://mma.prnewswire.com/media/755097/Taros_Chemicals_Logo.jpg )
(Photo: https://mma.prnewswire.com/media/755098/Taros_Management_Team.jpg )
Torsten has more than 20 years international R&D leadership experience, including 16 years at Roche in various roles of increasing responsibility such as Head of Medicinal Chemistry. His group created 52 new chemical lead series and more than 25 NCEs entered clinical trials as potential medicines. Torsten is the lead inventor of the anti-emetic medicine Netupitant, discovered at Roche and approved by the FDA as Akynzeo© in 2014. Moreover, he served in several management positions at Silence Therapeutics, Proteros Biostructures and Zealand Pharma. Torsten has been instrumental in developing the proprietary R&D portfolios of these biotech companies, with the most advanced assets being developed in clinical phase 3 trials.
Dr Dimitrios Tzalis, CEO Taros, comments:
"We are delighted that Torsten has joined Taros at this pivotal time for the company. As we continue to develop our drug discovery business, Torsten will add extensive industrial sector experience as well as an outstanding track record in medicinal chemistry and drug discovery collaborations. I am confident that Torsten will participate in shaping the future of Taros regarding integrated drug discovery and proprietary technologies."
Dr Torsten Hoffmann adds:
"These are exciting times for Taros currently providing expertise and tangible results to its partners through drug discovery campaigns in various therapeutic areas. Moreover, building on the enormous potential, created during the European Lead Factory, will be an excellent opportunity to further accelerate Taros' expansion into Drug Discovery."
About Taros Chemicals
Taros, a privately owned CRO has been serving pharmaceutical, biotech and chemical companies since 1999. Within our drug discovery services, our mission is to accelerate potential new medicines into clinical development. Taros adds considerable value to drug discovery collaborations to a boost clients' discovery programs from target validation, through hit identification, hit-to-lead and lead optimization. Taros' capabilities include innovative compound libraries, medicinal chemistry, computational sciences, bioscience and DMPK/physical sciences via its network. Taros has been leading the chemistry activities of the European Lead Factory (ELF), EU's 196 Million EUR early drug discovery platform.
https://www.taros.de
https://www.taros.de/cms/front_content.php?idcat=8&idart=345
Contact: Dr Dimitrios Tzalis Founder & CEO of Taros Chemicals GmbH & Co. KG Tel.: +49 (0)231 974272-11 e-mail: DTzalis(at)taros.de
SOURCE Taros Chemicals GmbH & Co. KG
Advertisement
Taros Chemicals GmbH & Co. KG announced the appointment of Dr Torsten Hoffmann as Senior Vice President Drug Discovery. In his role, Torsten will further strengthen and accelerate Taros' continued growth of its drug discovery business.
Advertisement
(Logo: https://mma.prnewswire.com/media/755097/Taros_Chemicals_Logo.jpg )
(Photo: https://mma.prnewswire.com/media/755098/Taros_Management_Team.jpg )
Torsten has more than 20 years international R&D leadership experience, including 16 years at Roche in various roles of increasing responsibility such as Head of Medicinal Chemistry. His group created 52 new chemical lead series and more than 25 NCEs entered clinical trials as potential medicines. Torsten is the lead inventor of the anti-emetic medicine Netupitant, discovered at Roche and approved by the FDA as Akynzeo© in 2014. Moreover, he served in several management positions at Silence Therapeutics, Proteros Biostructures and Zealand Pharma. Torsten has been instrumental in developing the proprietary R&D portfolios of these biotech companies, with the most advanced assets being developed in clinical phase 3 trials.
Dr Dimitrios Tzalis, CEO Taros, comments:
"We are delighted that Torsten has joined Taros at this pivotal time for the company. As we continue to develop our drug discovery business, Torsten will add extensive industrial sector experience as well as an outstanding track record in medicinal chemistry and drug discovery collaborations. I am confident that Torsten will participate in shaping the future of Taros regarding integrated drug discovery and proprietary technologies."
Dr Torsten Hoffmann adds:
"These are exciting times for Taros currently providing expertise and tangible results to its partners through drug discovery campaigns in various therapeutic areas. Moreover, building on the enormous potential, created during the European Lead Factory, will be an excellent opportunity to further accelerate Taros' expansion into Drug Discovery."
About Taros Chemicals
Taros, a privately owned CRO has been serving pharmaceutical, biotech and chemical companies since 1999. Within our drug discovery services, our mission is to accelerate potential new medicines into clinical development. Taros adds considerable value to drug discovery collaborations to a boost clients' discovery programs from target validation, through hit identification, hit-to-lead and lead optimization. Taros' capabilities include innovative compound libraries, medicinal chemistry, computational sciences, bioscience and DMPK/physical sciences via its network. Taros has been leading the chemistry activities of the European Lead Factory (ELF), EU's 196 Million EUR early drug discovery platform.
https://www.taros.de
https://www.taros.de/cms/front_content.php?idcat=8&idart=345
Contact: Dr Dimitrios Tzalis Founder & CEO of Taros Chemicals GmbH & Co. KG Tel.: +49 (0)231 974272-11 e-mail: DTzalis(at)taros.de
SOURCE Taros Chemicals GmbH & Co. KG
